Vanda Pharmaceuticals has failed to persuade the FDA to approve its gastroparesis candidate on the strength of a phase 3 ...

GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...

The fall flurry of biotech IPOs shows no signs of abating, with Upstream Bio becoming the latest company to express an ...

Medtronic is offering a peek into its ongoing, at-home trial of people with Parkinson’s disease being treated with adaptive ...

GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density ...

With COVID-19 still spreading and mpox emerging as a public health emergency of international concern, the National ...

Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...

After pushing back the decision date for Applied Therapeutics’ metabolic disorder drug govorestat, the FDA has now decided ...

Having already scooped up the U.S. rights to Capricor Therapeutics’ late-stage Duchenne muscular dystrophy (DMD) therapy, ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

For Ichnos Glenmark Innovation, good things come in threes. The alliance between Ichnos Sciences and Glenmark Pharmaceuticals ...